The advanced therapy supply chain is complex and made up of multiple moving parts. With milestone achievements such as the recent FDA approval of Novartis' CAR-T cell therapy Kymriah™ it's essential that we address the challenges of delivering these ground breaking therapies to patients on a global scale.
We recently participated in a webinar hosted by Cell and Gene Therapy Insights to share ways you can optimize your supply chain to support the shift from clinical to commercial scale manufacture and delivery. We discuss the importance of developing a robust, scaleable supply chain as part of your commercial strategy, as well as real-world case studies that illustrate the following:
- Unique challenges that may be encountered when planning your logistics strategy for an allogeneic or autologous therapy
- Importance of centralized control and communication throughout the supply chain
- Potential impact of early planning on risk mitigation and cost of goods in clinical supply chain management
To learn more, check out the webinar below!